Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

522126

	registered interest
	date	26/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	38833
	answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins> <del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p> </p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 10:57:37 question first ministerially corrected 13/06/2016 10:14:27 answering member 4020 label Biography information for George Freeman previous answer version 2228 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

225642

	registered interest
	date	06/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many NICE technology appraisals were carried out in respect of (a) infectious disease, (b) cancers and tumours, (c) disorders of the blood, (d) endocrine, nutritional and metabolic problems, (e) mental health disorders, (f) neurological, (g) cardiovascular disease, (h) musculoskeletal disorders and (i) other conditions in each of the last five years.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	226576
	answer	answer is ministerial correction date of answer 16/03/2015 answer text <p>The number of National Institute for Health and Care Excellence technology appraisals undertaken in respect of each disease category specified, for the last six financial years is shown in the attached table.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/03/2015 17:17:02 answering member 4020 label Biography information for George Freeman attachment 1 file name technology appraisals table.docx title NICE technology appraisals per disease catagory
	tabling member	1506 label Biography information for Andrew Gwynne

225664

	registered interest
	date	06/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many NICE technology appraisals have led to (a) positive, (b) negative and (c) other recommendations in each of the last five years; and if he will make a statement.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	226626
	answer	answer is ministerial correction date of answer 16/03/2015 answer text <p>A breakdown of National Institute for Health and Care Excellence (NICE) technology appraisal decisions by type of recommendation in each of the last six financial years is shown in the table. NICE classifies its technology appraisal decisions using four categories:</p><p> </p><p> </p><p> </p><ol start="1" type="i"><li>Recommended – recommended in line with the marketing authorisation or National Health Service clinical practice</li></ol><p> </p><p> </p><p> </p><ol start="2" type="i"><li>Optimised - recommended for a smaller subset of patients than stated in the marketing authorisation</li></ol><p> </p><p> </p><p> </p><ol start="3" type="i"><li>Only in research - recommended for use only in the context of a research study, for example a clinical trial</li></ol><p> </p><p> </p><p> </p><ol start="4" type="i"><li>Not recommended</li></ol><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Recommended</p></td><td><p>Optimised</p></td><td><p>Only in research</p></td><td><p>Not recommended</p></td></tr><tr><td><p>2014/15 (to 10 March)</p></td><td><p>23</p></td><td><p>3</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td><p>2013/14</p></td><td><p>15</p></td><td><p>8</p></td><td><p>1</p></td><td><p>8</p></td></tr><tr><td><p>2012/13</p></td><td><p>17</p></td><td><p>3</p></td><td><p>0</p></td><td><p>9</p></td></tr><tr><td><p>2011/12</p></td><td><p>20</p></td><td><p>4</p></td><td><p>1</p></td><td><p>15</p></td></tr><tr><td><p>2010/11</p></td><td><p>27</p></td><td><p>17</p></td><td><p>2</p></td><td><p>9</p></td></tr><tr><td><p>2009/10</p></td><td><p>13</p></td><td><p>2</p></td><td><p>0</p></td><td><p>7</p></td></tr></tbody></table><p> </p><p><em>Source:</em> NICE</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/03/2015 17:38:28 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

226030

	registered interest
	date	09/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what effect purdah will have on decision-taking on medicines currently under review by NICE; what assessment his Department has made of the potential effects of this on patient access to treatments; and if he will make a statement.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	226746
	answer	answer is ministerial correction date of answer 16/03/2015 answer text <p>Throughout the pre-election period, as in previous years, the National Institute for Health and Care Excellence (NICE) will continue the substantive work on the development of its guidance, including technology appraisals, such as evidence gathering and committee meetings, but will postpone publication of draft or final guidance until after the election. In the absence of NICE guidance on the use of a drug, commissioners should continue to make decisions on the availability of treatments based on an assessment of the available evidence. An absence of NICE guidance on a treatment alone is not an acceptable reason not to fund a treatment.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/03/2015 14:02:22 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

229131

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Strokes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will recommend to NICE that it updates the EQ5D methodology to better represent meaningful quality of life measures used in assessing cost-effectiveness for interventions that could affect the long-term survival of stroke patients with associated disability.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	228724
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the development of the methods it uses in the development of its guidance. NICE reviews its methods and processes periodically, including consultation with stakeholders, to ensure that they remain appropriate. Ministers are able to refer topics to NICE to be included in their work programme.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/03/2015 11:18:38 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

229134

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many training places for general practice were (a) commissioned and (b) filled in 2014-15 to date.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	228691
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The Government has mandated Health Education England (HEE) to provide national leadership on education, training and workforce development in the National Health Service in England.</p><p> </p><p> </p><p> </p><p>In 2014-15 HEE commissioned 3,067 general practitioner (GP) specialty training posts, and 2,688 were filled.</p><p> </p><p> </p><p> </p><p>Our mandate to HEE requires them to ensure a minimum of 3,250 trainees per year are recruited to GP training programmes in England by 2016. There are now 36,294 full time equivalent GPs working and training in the NHS, an increase of over 1,000 since September 2010.</p><p> </p><p> </p><p> </p><p>In January, a £10 million investment was announced to kick start a new plan to expand the general practice workforce. The plan covers a wide range of measures to recruit more aspiring medical students to take up a career in general practice, retain those doctors already working there, and provide support for those GPs who have taken a career break to get back into work.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/03/2015 14:07:45 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

229135

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Working Hours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to his contribution of 13 May 2013, Official Report, column 351, on health and social care, in what year he plans to end the ability of GPs to opt out of providing out-of-hours care.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	228692
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Since the introduction of the revised GP contract in 2004, general practitioners (GPs) have been able to opt out of responsibility for providing out-of-hours care.</p><p> </p><p> </p><p> </p><p>GP practices who provide out-of-hours services must meet the quality requirements set out in “National Quality Standards in the Delivery of out-of-hours services.” In order to bring back greater GP responsibility for their patients, from April 2014, under the terms of their contracts, where GPs do not provide out-of-hours services the practice must monitor the quality of out-of-hours services which are offered or provided to their patients having regard to the above guidance, act upon any concerns arising and report any concerns that they may have about the quality of these services.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/03/2015 14:04:50 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

387244

	registered interest
	date	02/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent representations he has received on possible links between quality of care, operational productivity and safe staffing levels from (a) Lord Carter, (b) Robert Francis and (c) others.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	5413
	answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>The Secretary of State for Health has received no correspondence or other written representations from Lord Carter on the possible links between quality of care, operational productivity and safe staffing levels. The Secretary of State met Lord Carter on 13 May 2015 and 18 May 2015 to discuss procurement. The Parliamentary Under-Secretary of State for NHS Productivity (Lord Prior) met with Lord Carter on 8 June 2015 and 1 July 2015 and had a telephone call with him on 21 May. In each case it was to receive an update on the work on improving operational productivity that Lord Carter is doing on behalf of the Department. I also met with Lord Carter very briefly on 29 June 2015 to discuss the work. On 11 June 2015 Lord Carter published his Interim report, <em><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/434202/carter-interim-report.pdf" target="_blank">Review of Operational Productivity in NHS providers</a></em>.</p><p> </p><p> </p><p> </p><p>The Secretary of State has received no correspondence or other written representations from Sir Robert Francis QC on the possible links between quality of care, operational productivity and safe staffing levels. The Secretary of State met Robert Francis on 19 January 2015 to discuss the <em><a href="https://freedomtospeakup.org.uk/wp-content/uploads/2014/07/F2SU_web.pdf" target="_blank">Freedom to Speak Up report</a></em> and on 9 February 2015 when the report was formally handed over.</p><p> </p><p> </p><p> </p><p>The Secretary of State and other Ministers regularly meet healthcare leaders and receive correspondence and other written representations on a wide range of issues, including safe staffing.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/07/2015 15:25:24 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

389555

	registered interest
	date	13/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Knee Replacements
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what representations he has received about development of a commissioning policy for microprocessor knees by NHS England.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	6563
	answer	answer is ministerial correction date of answer 21/07/2015 answer text <p>Since 1 July 2015, no Department of Health Minister or the Chief Medical Officer has received representations about development of a commissioning policy for microprocessor knees by NHS England.</p><p> </p><p><strong> </strong></p><p> </p><p>In November 2014 Baroness Jolly, the then Government Health Whip, was approached by PB Political Consulting about microprocessor knees, but no meeting was convened.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2015 11:51:47 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

389561

	registered interest
	date	13/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the criteria and processes are for a technology to be considered for NHS England's evaluation through commissioning programme.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	6559
	answer	answer is ministerial correction date of answer 21/07/2015 answer text <p>NHS England has advised that it has a Standard Operating Procedure in place to support the development, consideration and implementation of individual schemes within its overall Commissioning through Evaluation programme. Potential schemes may come from a number of sources. All will need to demonstrate that they can generate valuable new data on a specialised treatment that is not routinely commissioned on the basis of currently available evidence on clinical and cost effectiveness, but nonetheless shows significant promise as a future treatment.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2015 11:35:06 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne